Eleusian is a private company focused on the development of medical devices and therapeutics for specific
diseases. It is collaborating with a multidisciplinary team of scientists and physicians at the Miller School
of Medicine at the University of Miami to develop effective therapeutics for the treatment of mild traumatic
brain injury/concussion (“mTBI”) with post-traumatic stress disorder (“PTSD”) or PTSD alone, using
psilocybin and N-Acetylcysteine (“NAC”). NAC has been shown to be safe and efficacious in a phase I
human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to
demonstrate the efficacy of the combination of psilocybin and NAC in the treatment of mTBI with PTSD
in established rodent models. The research team at the Miller School of Medicine has a license from the
United States Drug Enforcement Administration to conduct research using Schedule I controlled
substances, which includes psilocybin.
The Eleusian management team includes seasoned capital markets and life sciences executives. CEO and
director, Jonathan Gilbert, had a successful prior exit in the psychedelic space and was the CEO of Scythian
Biosciences, Inc., a publicly traded research and development company focusing on the prevention and
treatment of concussions and traumatic brain injury using a proprietary cannabinoid combination. Mr.
Gilbert is also experienced in strategic investments and partnerships related to the cultivation, distribution
and retail sale of legal cannabis.
Maghsoud Dariani, Chief Science Officer, has years of expertise with life sciences companies. He is
currently also President and CEO of Semorex Inc., a privately held company focused on the discovery and
development of novel therapeutics for cancer. Prior to joining Semorex, Mr. Dariani was President of Focus
Pharmaceuticals, Inc., where he managed the development and approval of drug products, achieving an
FDA approval and bringing another to the clinical evaluation stage. He subsequently negotiated the
successful sale of the company in February 2003. Prior to Focus, Mr. Dariani was Vice President of the
chiral pharmaceutical business unit at Celgene Corporation. During histwelve years at Celgene, Mr. Dariani
was responsible for the successful development and FDA approval of the chirally pure versions of Ritalin,
which are currently marketed by Novartis under the Focalin and Focalin XR trade names.
